Search results for " titers" in Articles / App Notes
Article
Single-Use Technologies Prove Effective for Viral Vector Process Development
…ines for viral vector production combined with the use of large single-use bioreactors for increased titers and reduced costs.
References
1. R. Legmann, Cytotherapy, 22(5) Supplement S151…
Article
Optimizing Late-Stage and Commercial Cell-Culture Processes
In the early 1990s, cell titers for monoclonal antibodies (mAbs) were in the range of 50–100 mg/L, notes Dr. Andy Racher, associate director future technologies, Lonza Pharma & Biotech. Today, however…
Article
Fifteen Years of Progress: Biopharmaceutical Industry Survey Results
BioPlan has also reported data and trends for bioprocessing titers and yields over the past 30 or more years (5). Average commercial-scale titers have increased from estimated 1.1 g/L in 2003 to curre…
Article
Single-use Bioreactors Have Reached the Big Time
Improvements in cell-culture processes have led to higher titers and thus higher cell densities, which have facilitated the adoption of single-use bioreactors through reductions in needed reactor volu…
Article
Addressing the Challenges in Downstream Processing Today and Tomorrow
Increasing upstream titers and shrinking development timelines have posed several challenges to downstream process development of mAbs. Some of the major strategies and tools to address these challeng…
Article
Advances in Sterilization Technologies for Overcoming Viral-Vector Manufacturing Challenges
Sterility must be assured for all biologic drug products. Terminal sterilization achieved via treatment with heat, radiation, or certain chemicals (vaporous hydrogen peroxide, vaporous peracet…
Article
State of the Biopharmaceutical Industry: Lessons from 2018 Survey Data
For example, our studies have shown rather consistent incremental increases in upstream cell culture titers over the past three decades; and it took well over a decade for single-use equipment to atta…
Article
Making the Move to Continuous Chromatography
Manufacturers are always trying to optimize their processes, particularly as product titers increase, according to Levison. In the case of antibodies, the industry is now working well above 3 g/L, eve…
Article
Impact of Media Components on CQAs of Monoclonal Antibodies
The authors review how media components modulate the quality of monoclonal antibody products.
By Anurag Rathore, Rajinder Kaur, Dipankar Borgayari
Recombinant protein products have…
Article
Fusion Proteins Pose Manufacturability Challenges
The titers for fusion proteins are generally lower than those for mAbs due to less efficient translation, notes Chamow.
Non-human glycans—such as N-glycolylneuraminic acid and alpha-galactose—are …